report revenues/gaap ep vs consensu
estim recal guidanc suspend
amid uncertainti patient educ session go virtual though
attend far people/sess dtc spend increas sequenti
refocus radio/tv larg market digital/tv smaller market
per januari initi report challeng proper patient select
necessit high cost busi remain concern valuat
current revenu priorit elect procedur like
ua covid rebound adjust estim higher opex go forward
result revenu line estim rev
us line estim us asp ou rev
ou asp ep miss estim
consensu opex estim gm beat
estim manufactur effici
metric new us center ad vs
actual implants/ctr vs vs dtc spend/
patient vs vs math
suggest patient us got implant average acquisit cost
updat implant resum state schedul next
week back earli level dise inpati sleep studi also
constrain may see gap patient funnel challeng expect
convert patient funnel final implant given competit time compani
look open asc allow case done
dtc virtual tool util dtc outreach includ virtual health talk
said along busi model reli heavi dtc funnel
patient educ session hospit follow consults/evals/impl
move virtual framework fundament effici time patient
acquisit actual implant bound lengthen
rais limit consist medicar japan
reimburs delay pediatr age expans
initi step gener us pediatr indic inspir app patient smartphon
could use tool gather patient-level data question though remain
data mine use guid care
year price histori
inspir manufactur market
devic use treat sleep apnea
analyst certif import disclosur see disclosur
inspir first compani commerci hypogloss
nerv stimul hgn pull tongu forward therefor
improv airway patenc obstruct sleep apnea osa
patient point due dilig field
check point therapi role osa
necessarili cure-al matter big tam
moreov inher challeng adopt therapi
outcom assess lot complic
believ properli appreci street
compani continu grow
real-world outcom mirror trial
patient acquisit cost reduc drastic implants/cent
jump significantli level current
real-world outcom better trial
reimburs rate improv ua reimburs pressur
cpap continu declin
patient acquisit cost increas implants/cent remain
rel static
real-world outcom wors trial
competitor nyxoah privat imthera part
price target calcul use multipl sale estim entir med-tech
univers trade forward p/ multipl compound-annual-growth-rate inspir believ deserv premium med-tech space given
novel natur technolog effect select patient
expect inspir ua therapi reflect forward estim high challeng find right patient receiv
therapi make estim pro forma number difficult street estim current factor execut risk stori see thing
patient select remain achil heel therapi compani need spend signific dollar patient educ
fraction patient seem like eventu get therapi
stori market risk need factor
statement oper
good sold
unreal loss inv
sg
